Clinical trials: Chronic Noncancer Pain
Constipation
Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01275755
- Testing
- ADL5945 0.25 mg
- Volunteers
- 81 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pain
A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.
The purpose of this study is to compare the effectiveness and safety of sustained- release hydromorphone, formulated to release slowly over time, taken once daily, and controlled- release oxycodone taken twice daily, in patients…
- Trial name
- NCT00261495
- Testing
- OROS hydromorphone HCl, Oxycodone
- Where
- 52 sites in Czechia, Denmark and 8 more
- Volunteers
- 504 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Noncancer Pain
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
The study will provide information to assess the benefits versus risks of extended exposure to oxycodone HCl and naltrexone HCl extended-release capsules in a chronic noncancer pain population.
- Trial name
- NCT01428583
- Testing
- oxycodone HCl and naltrexone HCl extended-release capsules
- Where
- 32 sites in United States
- Volunteers
- 395 people
- Sponsor
- Pfizer
Chronic Pain
Comparative Effectiveness Trial of Communication Strategies in the Management of Chronic Pain
Investigators will compare Clinical Decision Support (CDS) versus Patient Education and Activation Tools (PEATs) in patients prescribed long-term or multiple opioids to measure outcomes that are important to patients.
- Trial name
- NCT03301623
- Testing
- Clinical Decision Support, Patient Education and Activation Tools
- Where
- United States
- Volunteers
- 983 people
- Sponsor
- Cedars-Sinai Medical Center
Opioid Induced Constipation
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01207427
- Testing
- ADL5945 0.1 mg, ADL5945 0.25 mg
- Volunteers
- 131 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)